[{"NetIncomeLoss_2_Q2_USD":-1915000.0,"AssetsCurrent_0_Q2_USD":221283000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q2_USD":2123000.0,"GoodwillForeignCurrencyTranslationGainLoss_2_Q2_USD":8000.0,"InterestIncomeExpenseNonoperatingNet_1_Q2_USD":-169000.0,"InterestIncomeExpenseNonoperatingNet_2_Q2_USD":110000.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1_Q2_USD":209000.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2_Q2_USD":80000.0,"GoodwillImpairmentLoss_1_Q2_USD":0.0,"GoodwillImpairmentLoss_2_Q2_USD":18144000.0,"AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1_Q2_USD":59000.0,"CertificatesOfDepositAtCarryingValue_0_Q2_USD":7500000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-94802000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":-5818000.0,"InventoryFinishedGoodsNetOfReserves_0_Q2_USD":33680000.0,"GainLossOnSaleOfPropertyPlantEquipment_2_Q2_USD":-265000.0,"RepaymentsOfLongTermDebt_2_Q2_USD":351000.0,"IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_2_Q2_USD":1900000.0,"SellingGeneralAndAdministrativeExpense_2_Q2_USD":28981000.0,"DepreciationAndAmortization_2_Q2_USD":6459000.0,"SellingGeneralAndAdministrativeExpense_1_Q2_USD":14550000.0,"ProceedsFromIssuanceOfLongTermDebt_2_Q2_USD":50000000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":23196000.0,"ShareBasedCompensation_2_Q2_USD":2033000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q2_USD":209000.0,"Assets_0_Q2_USD":440525000.0,"InventoryWorkInProcessNetOfReserves_0_Q2_USD":11914000.0,"CommonStockSharesIssued_0_Q2_shares":14204000.0,"FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q2_USD":128000.0,"NumberOfReportingUnits_2_Q2_pure":2.0,"FinanceLeaseLiabilityUndiscountedExcessAmount_0_Q2_USD":57000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":2240000.0,"StockIssuedDuringPeriodValueShareBasedCompensation_1_Q2_USD":68000.0,"InventoryValuationReserves_0_Q2_USD":1900000.0,"FinanceLeaseInterestExpense_1_Q2_USD":8000.0,"FinanceLeaseInterestExpense_2_Q2_USD":15000.0,"FinanceLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":166000.0,"CostOfGoodsAndServicesSold_1_Q2_USD":16936000.0,"CostOfGoodsAndServicesSold_2_Q2_USD":31136000.0,"FinanceLeaseLiabilityNoncurrent_0_Q2_USD":429000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.01,"MarketableSecuritiesCurrent_0_Q2_USD":27624000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"IntangibleAssetsGrossExcludingGoodwill_0_Q2_USD":118859000.0,"BusinessAcquisitionsProFormaRevenue_1_Q2_USD":30678000.0,"BusinessAcquisitionsProFormaRevenue_2_Q2_USD":70028000.0,"IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2_Q2_USD":300000.0,"CommonStockValue_0_Q2_USD":142000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":-1997000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":-417000.0,"AccountsReceivableNetCurrent_0_Q2_USD":24094000.0,"IncreaseDecreaseInAccruedLiabilities_2_Q2_USD":-5135000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":14199000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":14201000.0,"InventoryWriteDown_2_Q2_USD":3259000.0,"EarningsPerShareBasic_1_Q2_USD":-0.54,"EarningsPerShareBasic_2_Q2_USD":-0.13,"FiniteLivedIntangibleAssetsAccumulatedAmortization_0_Q2_USD":17118000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":4532000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":10582000.0,"EffectiveIncomeTaxRateContinuingOperations_2_Q2_pure":0.179,"ProvisionForDoubtfulAccounts_2_Q2_USD":-36000.0,"EffectiveIncomeTaxRateContinuingOperations_1_Q2_pure":0.206,"BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_2_Q2_USD":-20326000.0,"GainLossOnInvestments_2_Q2_USD":0.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":50609000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":21414000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":116746000.0,"OtherAssetsNoncurrent_0_Q2_USD":13451000.0,"AmortizationOfIntangibleAssets_1_Q2_USD":2200000.0,"AmortizationOfIntangibleAssets_2_Q2_USD":3500000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":-2462000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-7499000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-1835000.0,"FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q2_USD":174000.0,"AccruedLiabilitiesAndOtherLiabilities_0_Q2_USD":21745000.0,"IncreaseDecreaseInInventories_2_Q2_USD":5410000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_2_Q2_USD":20000000.0,"CostsAndExpenses_1_Q2_USD":40214000.0,"CostsAndExpenses_2_Q2_USD":68517000.0,"BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1_Q2_USD":4196000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":49517000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.01,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q2_USD":8405000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q2_USD":2059000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_Q2_USD":-45000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":6340000.0,"AccountsPayableCurrent_0_Q2_USD":6162000.0,"LiabilitiesCurrent_0_Q2_USD":27907000.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q2_USD":2304000.0,"BusinessCombinationContingentConsiderationLiabilityCurrent_0_Q2_USD":11688000.0,"BusinessAcquisitionsProFormaNetIncomeLoss_1_Q2_USD":-7708000.0,"BusinessAcquisitionsProFormaNetIncomeLoss_2_Q2_USD":-917000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":14201000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":14199000.0,"InventoryRawMaterialsNetOfReserves_0_Q2_USD":13851000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":4613000.0,"PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_Q2_USD":200000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":-9705000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":-2332000.0,"Goodwill_0_Q2_USD":33958000.0,"FinanceLeaseWeightedAverageDiscountRatePercent_0_Q2_pure":0.05,"ProceedsFromStockOptionsExercised_2_Q2_USD":68000.0,"PaymentsToAcquireMarketableSecurities_2_Q2_USD":20035000.0,"LongTermDebtNoncurrent_0_Q2_USD":50000000.0,"FinanceLeaseLiabilityPaymentsDueYearThree_0_Q2_USD":160000.0,"NetIncomeLoss_1_Q2_USD":-7708000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":52659000.0,"BusinessCombinationContingentConsiderationLiabilityNoncurrent_0_Q2_USD":37062000.0,"InventoryNoncurrent_0_Q2_USD":12966000.0,"CapitalExpendituresIncurredButNotYetPaid_2_Q2_USD":61000.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"DeferredIncomeTaxLiabilitiesNet_0_Q2_USD":14855000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q2_USD":116746000.0,"ShortTermLeaseCost_1_Q2_USD":0.0,"ShortTermLeaseCost_2_Q2_USD":0.0,"FinanceLeaseLiabilityPaymentsDueYearFour_0_Q2_USD":44000.0,"WeightedAverageNumberDilutedSharesOutstandingAdjustment_1_Q2_shares":0.0,"WeightedAverageNumberDilutedSharesOutstandingAdjustment_2_Q2_shares":0.0,"OperatingLeaseWeightedAverageDiscountRatePercent_0_Q2_pure":0.041,"FinanceLeaseRightOfUseAssetAmortization_1_Q2_USD":49000.0,"FinanceLeaseRightOfUseAssetAmortization_2_Q2_USD":86000.0,"IntangibleAssetsNetExcludingGoodwill_0_Q2_USD":95978000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":1018000.0,"EarningsPerShareDiluted_1_Q2_USD":-0.54,"EarningsPerShareDiluted_2_Q2_USD":-0.13,"CommonStockSharesOutstanding_0_Q2_shares":14204000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":3212000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":440525000.0,"OperatingLeaseCost_1_Q2_USD":595000.0,"OperatingLeaseCost_2_Q2_USD":1169000.0,"DeferredIncomeTaxExpenseBenefit_2_Q2_USD":-907000.0,"PreferredStockValue_0_Q2_USD":0.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_Q2_pure":0.0,"InventoryNet_0_Q2_USD":46479000.0,"IncreaseDecreaseInAccruedIncomeTaxesPayable_2_Q2_USD":-389000.0,"PaymentsForRepurchaseOfCommonStock_2_Q2_USD":0.0,"OperatingIncomeLoss_1_Q2_USD":-9536000.0,"OperatingIncomeLoss_2_Q2_USD":-2442000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":66075000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":30678000.0,"CommonStockSharesAuthorized_0_Q2_shares":90000000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":373000.0,"PaymentsToAcquireBusinessesNetOfCashAcquired_2_Q2_USD":93859000.0,"PreferredStockSharesAuthorized_0_Q2_shares":1250000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":2033000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":2240000.0,"ImpairmentOfIntangibleAssetsFinitelived_2_Q2_USD":1025000.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":-6208000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":-40717000.0,"LeaseCost_1_Q2_USD":726000.0,"LeaseCost_2_Q2_USD":1407000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":243511000.0,"VariableLeaseCost_1_Q2_USD":74000.0,"VariableLeaseCost_2_Q2_USD":137000.0,"AllowanceForDoubtfulAccountsReceivableCurrent_0_Q2_USD":981000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q2_USD":1195000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":908000.0,"GoodwillAcquiredDuringPeriod_2_Q2_USD":44400000.0,"FinanceLeaseLiabilityCurrent_0_Q2_USD":186000.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":843000.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1_Q2_USD":593000.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2_Q2_USD":1137000.0,"RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_1_Q2_USD":59000.0,"RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_2_Q2_USD":110000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":1476000.0,"StockholdersEquity_0_Q2_USD":288444000.0,"AccruedProfessionalFeesCurrent_0_Q2_USD":3052000.0,"Ticker":"ANIK","CIK":"898437","name":"ANIKA THERAPEUTICS, INC.","OfficialName":"Anika Therapeutics Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"2","uom":"USD","footnote":"nan","Market Cap":"337949354.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Electromedical & Electrotherapeutic Apparatus","Market":"NASDAQ","SP500":"nan","filed":"20200807"}]